MacKay Jimeson, Executive Director of Patients Rising, breaks down the most recent announcement from the White House that they may begin using their “march-in” rights on patents to try to curb drug prices. Hear why Jimeson says this is a bad idea. Plus, a reversal on a decision from a large insurer that is actually good for patients. 

NPR News Article: White House Proposes to 'March In' On Patents or Costly Drugs

Politico Pulse News Article: Aetna Changes Telehealth Coverage